- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01100827
A Retrospective Molecular Epidemiology Study in Singapore Patients With Advanced Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Histology to Assess Epidermal Growth Factor Receptor (EGFR) Mutation Status
December 10, 2013 updated by: National University Hospital, Singapore
To determine EGFR mutation status in patients with advanced stage adenocarcinoma NSCLC.
To determine the association between EGFR mutation status and demographic data in advanced stage adenocarcinoma NSCLC patients.
Study Overview
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- National University Hospital Singapore
-
Contact:
- Ross Andrew Soo, MBBS
- Phone Number: 65 6772 4624
- Email: Ross_Soo@nuhs.edu.sg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
In order to determine the EGFR mutation status, data analysis will be performed on demographic data and medical records (i.e.
case notes and pathology reports) from patient with advanced stage adenocarcinoma NSCLC
Description
Inclusion Criteria:
Nil
Exclusion Criteria:
Nil
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
EGFR mutation status in patients
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 Mar 2;97(5):339-46. doi: 10.1093/jnci/dji055.
- Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004 Mar 15;22(6):1103-9. doi: 10.1200/JCO.2004.08.158.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (Anticipated)
February 1, 2015
Study Completion (Anticipated)
February 1, 2015
Study Registration Dates
First Submitted
April 7, 2010
First Submitted That Met QC Criteria
April 8, 2010
First Posted (Estimate)
April 9, 2010
Study Record Updates
Last Update Posted (Estimate)
December 11, 2013
Last Update Submitted That Met QC Criteria
December 10, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NS01/03/10
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NSCLC
-
Jianxing HeInnovent Biologics (Suzhou) Co. Ltd.RecruitingNeoadjuvant Therapy | KRAS G12C Mutation | Resectable NSCLC | Stage IB-IIIA NSCLCChina
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Fondazione Ricerca TraslazionaleRecruiting
-
Peking Union Medical CollegeRecruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
Xinqiao Hospital of ChongqingCompleted
-
Seoul St. Mary's HospitalBoehringer IngelheimActive, not recruiting
-
Taipei Veterans General Hospital, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Tri-Service... and other collaboratorsUnknown
Clinical Trials on EGFR mutation status in patients
-
Postgraduate Institute of Dental Sciences RohtakCompleted
-
Centre Hospitalier Universitaire de la RéunionCompletedSquamous Cell Lung CancerRéunion
-
AstraZenecaCompletedEGFR Mutation Status in aNSCLC PatientsKorea, Republic of, Russian Federation, Malaysia, China, Australia, Taiwan, Thailand, Indonesia, Singapore
-
University of MilanActive, not recruitingDiabetic Nephropathy Type 2Italy
-
Anthony MaglioccoRecruiting
-
Changi General HospitalCompleted
-
Konya Beyhekim Training and Research HospitalCompleted
-
Institut BergoniéAstraZenecaCompletedNon Small Cell Lung Cancer | Advanced Solid TumorFrance
-
AstraZenecaCompletedNon Small Cell Lung CancerVietnam, Philippines, China, Hong Kong, Taiwan, Thailand, India
-
AGO Research GmbHCompleted